Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLM NASDAQ:CDIO NASDAQ:HCWB NASDAQ:PTIX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLMApollomics$5.45-7.8%$6.15$4.47▼$35.98$6.26M0.9250,183 shs10,891 shsCDIOCardio Diagnostics$3.63-9.7%$3.99$3.22▼$53.10$6.31M2.9642,634 shs33,063 shsHCWBHCW Biologics$4.09-5.8%$4.52$3.55▼$100.80$5.89M0.66111,372 shs29,095 shsPTIXAtrinsic$2.93-4.6%$3.33$2.35▼$15.54$1.73M0.34112,897 shs67,838 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLMApollomics-7.86%-4.05%-9.32%+4.99%-59.36%CDIOCardio Diagnostics-9.70%+5.22%-21.09%-5.47%-71.19%HCWBHCW Biologics-5.76%-11.47%-14.61%-54.30%-82.37%PTIXAtrinsic-4.56%+3.53%-15.07%-3.30%-67.08%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPLMApollomics0.4342 of 5 stars0.03.00.00.03.30.00.0CDIOCardio Diagnostics2.6201 of 5 stars3.53.00.00.01.91.70.6HCWBHCW Biologics2.162 of 5 stars3.53.00.00.01.61.70.0PTIXAtrinsic1.0018 of 5 stars0.03.00.00.03.81.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLMApollomics 0.00N/AN/AN/ACDIOCardio Diagnostics 3.00Buy$60.001,552.89% UpsideHCWBHCW Biologics 3.00Buy$35.00755.75% UpsidePTIXAtrinsic 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PTIX, APLM, HCWB, and CDIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025HCWBHCW BiologicsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$120.00 ➝ $35.00(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLMApollomics$1.49M4.02N/AN/A$4.48 per share1.22CDIOCardio Diagnostics$40K157.91N/AN/A$7.10 per share0.51HCWBHCW Biologics$2.57M2.29N/AN/A($6.08) per share-0.67PTIXAtrinsicN/AN/AN/AN/A$1.96 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLMApollomics-$53.86MN/A0.00∞N/AN/AN/AN/AN/ACDIOCardio Diagnostics-$8.38MN/A0.00∞N/A-30,465.10%-76.14%-68.47%8/18/2025 (Estimated)HCWBHCW Biologics-$30.02M-$23.25N/A∞N/A-1,712.94%N/A-90.09%N/APTIXAtrinsic-$5.53M-$13.11N/A∞N/AN/A-860.52%-354.19%N/ALatest PTIX, APLM, HCWB, and CDIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CDIOCardio Diagnostics-$1.80-$0.97+$0.83-$0.97$0.08 million$0.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPLMApollomicsN/AN/AN/AN/AN/ACDIOCardio DiagnosticsN/AN/AN/AN/AN/AHCWBHCW BiologicsN/AN/AN/AN/AN/APTIXAtrinsicN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLMApollomicsN/A1.391.39CDIOCardio DiagnosticsN/A19.4719.47HCWBHCW BiologicsN/A0.070.07PTIXAtrinsicN/A0.860.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLMApollomics19.13%CDIOCardio Diagnostics8.06%HCWBHCW Biologics2.96%PTIXAtrinsic7.97%Insider OwnershipCompanyInsider OwnershipAPLMApollomicsN/ACDIOCardio Diagnostics22.30%HCWBHCW Biologics42.70%PTIXAtrinsic35.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLMApollomics451.10 millionN/ANot OptionableCDIOCardio Diagnostics11.74 million1.35 millionNot OptionableHCWBHCW Biologics401.44 million825,000Not OptionablePTIXAtrinsic2589,000383,000Not OptionablePTIX, APLM, HCWB, and CDIO HeadlinesRecent News About These CompaniesProtagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug CandidatesJuly 30, 2025 | prismmediawire.comPProtagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug CandidatesJuly 30, 2025 | globenewswire.comProtagenic Therapeutics, Inc. (PTIX) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comProtagenic & Phytanix Merge in All-Stock Move, Sparking Retail FrenzyMay 29, 2025 | msn.comProtagenic Therapeutics swaps warrants for sharesMay 21, 2025 | uk.investing.comProtagenic Therapeutics and Phytanix merge in all stock dealMay 21, 2025 | thepharmaletter.comTProtagenic Therapeutics Receives $3.1 Million from Recent Warrant ActivityMay 21, 2025 | accessnewswire.comAProtagenic Therapeutics Shares Double After Buyout Offer From Phytanix BioMay 20, 2025 | marketwatch.comProtagenic Therapeutics stock soars on merger to create Neuroactive Biopharmaceutical companyMay 20, 2025 | in.investing.comProtagenic Therapeutics Merges With Phytanix Bio In All-Stock Deal: Retail Turns Extremely BullishMay 20, 2025 | msn.comProtagenic Therapeutics Soars 190% on Merger to Launch Neuroactive Biopharma FirmMay 20, 2025 | msn.comPTIX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Protagenic Therapeutics, Inc. Is Fair to ShareholdersMay 19, 2025 | businesswire.comProtagenic Therapeutics and Phytanix Announce Business Combination to form Neuroactive Biopharmaceutical Company with Six Drug Candidates in Development including Treatments for Obesity and Metabolic DisordersMay 19, 2025 | accessnewswire.comAProtagenic Therapeutics Inc.May 9, 2025 | barrons.comProtagenic Therapeutics, Inc.: Protagenic Therapeutics to Effect 1-for-14 Reverse Stock SplitApril 29, 2025 | finanznachrichten.deProtagenic Therapeutics to Effect 1-for-14 Reverse Stock SplitApril 29, 2025 | accessnewswire.comAProtagenic Therapeutics adjusts stock option pricesFebruary 26, 2025 | uk.investing.comPTIX stock touches 52-week low at $0.25 amid sharp annual declineFebruary 11, 2025 | msn.comAvalon Holdings (AMEX:AWX) Stock Quotes, Forecast and News SummaryJanuary 30, 2025 | benzinga.comPerformance Tech stock hits 52-week low at $0.4January 30, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePTIX, APLM, HCWB, and CDIO Company DescriptionsApollomics NASDAQ:APLM$5.45 -0.46 (-7.78%) Closing price 08/15/2025 03:55 PM EasternExtended Trading$5.59 +0.14 (+2.57%) As of 08/15/2025 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.Cardio Diagnostics NASDAQ:CDIO$3.63 -0.39 (-9.70%) Closing price 08/15/2025 03:59 PM EasternExtended Trading$3.64 +0.02 (+0.41%) As of 08/15/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.HCW Biologics NASDAQ:HCWB$4.09 -0.25 (-5.76%) Closing price 08/15/2025 03:59 PM EasternExtended Trading$4.37 +0.28 (+6.85%) As of 08/15/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.Atrinsic NASDAQ:PTIX$2.93 -0.14 (-4.56%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$2.84 -0.09 (-3.07%) As of 08/15/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNH AI Glasses to Replace Smartphones? Meta Is Taking Aim at Apple Deere’s Sell-Off Could Be a Long-Term Buying Chance 3 Restaurant Stocks That Will Outperform in Q3 and Q4 Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore The Real Reason Ford Stock Is Rallying—Can It Keep Going? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access